學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
OrganiGram: Navigating the Cannabis Industry with "Grey Knowledge"
內容大綱
OrganiGram Holdings Inc. (OrganiGram), a New Brunswick-based company, was a licensed producer of medical cannabis in Canada. On April 20, 2016, the Canadian government announced that legislation to legalize recreational cannabis would be introduced in the spring of 2017 with the intention of having it become law in the spring of 2018. The announcement triggered expansion activities at all of Canada's largest licensed producers of cannabis. However, there were many unknowns in terms of how the legalization of recreational cannabis would happen. What would the timeline be? Who would be allowed to grow cannabis? In anticipation of regulatory changes, OrganiGram needed to analyze the Canadian cannabis industry and engage in a scenario-planning exercise. How could OrganiGram move through this time of uncertainty, while both creating a strategy for the anticipated recreational cannabis market and continuing to work on its medical cannabis sales?